Key result
Moxonidine showed comparable blood pressure reduction to enalapril but additionally normalized the 24-hour BP profile and reduced BP variability in patients with metabolic syndrome.
Why the study?
The study was conducted to evaluate the efficacy of the imidazoline receptor agonist moxonidine compared to the ACE inhibitor enalapril in patients with arterial hypertension and metabolic syndrome.
Does moxonidine improve blood pressure control and vascular parameters compared to enalapril in patients with arterial hypertension and metabolic syndrome?
RCT (n=50)
randomized
Does moxonidine improve blood pressure control and vascular parameters compared to enalapril in patients with arterial hypertension and metabolic syndrome?
In patients with hypertension and metabolic syndrome, moxonidine provides comparable blood pressure lowering to enalapril but offers additional benefits on blood pressure variability and cerebrovascular reactivity.
No takes yet. Share an insight, caveat, or question.
Moxonidine may warrant preference over enalapril for normalized 24-hour BP in metabolic syndrome hypertension; extends RCT evidence on variability reduction.
Гапон et al. (2019) conducted an RCT in Arterial hypertension and metabolic syndrome (n=50). Moxonidine vs. Enalapril (5-15 mg per day) was evaluated on Changes in office BP, average 24-hour BP, average day-time and night-time BP. Moxonidine showed comparable blood pressure reduction to enalapril but additionally normalized the 24-hour BP profile and reduced BP variability in patients with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: